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ABSTRACT 3 
BACKGROUND CONTEXT: A previous study demonstrated that in seniors, the presence of 4 
cervical musculoskeletal impairment was not specific to cervicogenic headache but was present 5 
in various recurrent headache types. Physiotherapy treatment is indicated in those seniors 6 
diagnosed with cervicogenic headache but could also be adjunct treatment for those with 7 
cervical musculoskeletal signs who are suspected of having transitional headaches. 8 
PURPOSE: To determine the effectiveness of a physiotherapy program for seniors with 9 
recurrent headaches associated with neck pain and cervical musculoskeletal dysfunction, 10 
irrespective of the headache classification. 11 
STUDY DESIGN: Prospective, stratified, randomized controlled trial with blinded outcome 12 
assessment.  13 
PATIENT SAMPLE: Sixty-five participants with recurrent headache, aged 50-75 years were 14 
randomly assigned to either a physiotherapy (n =33) or usual care group (n = 32). 15 
OUTCOME MEASURES: The primary outcome was headache frequency. Secondary 16 
outcomes were headache intensity and duration, neck pain and disability, cervical range of 17 
motion, quality of life, participant satisfaction and medication intake.  18 
METHODS: Participants in the physiotherapy group received 14 treatment sessions. 19 
Participants in the usual care group continued with their usual care. Outcome measures were 20 
recorded at baseline, 11 weeks, 6 months and 9 months. This study was funded by a 21 
government research fund of $6850. No conflict of interest is declared.  22 
RESULTS: There was no loss to follow-up for the primary outcome measure. Compared to 23 
usual care, participants receiving physiotherapy reported significant reductions in headache 24 
frequency immediately after treatment (mean difference -1.6 days, 95% CI -2.5 to -0.6), at the 25 
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6-month follow-up (-1.7 days, 95% CI -2.6 to -0.8), at the 9-month follow-up (-2.4 days, 95% 1 
CI -3.2 to -1.5) and significant improvements in all secondary outcomes immediately post-2 
treatment and at the 6- and 9-month follow-ups, (p < 0.05 for all). No adverse events were 3 
reported. 4 
CONCLUSION: Physiotherapy treatment provided benefits over usual care for seniors with 5 
recurrent headache associated with neck pain and dysfunction.  6 
 7 
KEY WORDS: cervical disorder, headache, neck pain, physiotherapy, seniors 8 
 9 
  10 
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Introduction 1 
Headache is a common health problem that affects quality of life. Headaches change with age 2 
[1-3]. Their features become less typical, for example, a diagnosis of probable migraine is 3 
more prevalent in seniors than migraine [4]. Secondary headaches increase in frequency [5] 4 
and associated neck pain is common [2]. In line with this occurrence, we demonstrated that 5 
cervical musculoskeletal dysfunction (CMD) was more prevalent in seniors with, than without 6 
headache. CMD was not specific to cervicogenic headache but was present in various recurrent 7 
headache types (e.g. migraine, tension-type headache) [6]. Nevertheless, the degree of CMD 8 
was variable. We characterised it as greater or lesser based principally on loss of motion and 9 
pain on palpation of cervical joints. We found that greater or lesser dysfunction likewise was 10 
not related to headache classification or length of headache history, albeit that there was a trend 11 
for more cervicogenic headaches to be in the group with greater neck dysfunction. The CMD 12 
and neck pain in seniors might be the source of headache (cervicogenic headache), or a 13 
prevalent co-morbid feature and possibly an additional peripheral source of nociception in 14 
primary headaches as part of their changing nature with ageing. 15 
 16 
Changes in the nature of headache with age play an important role in the choice of treatment. 17 
The effective management of headache in seniors remains a challenge. There is evidence that 18 
physiotherapy methods are effective for treating the CMD of cervicogenic headache [7, 8]. It is 19 
unknown if management of the neck could be a useful adjunct treatment for those seniors with 20 
other recurrent headaches as probable migraine when they are associated with neck pain and 21 
CMD. This is a safe option given the widespread concerns about medication overuse, adverse 22 
drug events and drug interactions in senior populations [9, 10]. Management of CMD may 23 
reduce headache frequency or severity, enhance the quality of life, and lessen medication use, 24 
cost and adverse drug events. 25 
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 1 
This trial was undertaken to determine the effectiveness of a physiotherapy program of cervical 2 
mobilization and therapeutic exercise for seniors with recurrent headache irrespective of 3 
headache classification, provided there was associated with neck pain and CMD. We 4 
hypothesized that treatment of the neck disorder would be more effective in reducing headache 5 
frequency than usual care and as secondary outcomes, would result in greater improvements in 6 
headache duration and intensity, cervical range of motion, neck pain and disability, medication 7 
use, quality of life and participant’s perception of treatment benefit. If treatment of the neck 8 
proved effective, we planned subgroup analyses to determine if there was a difference in effect 9 
if the headache was diagnosed as cervicogenic or whether greater or lesser musculoskeletal 10 
dysfunction was judged to be present. 11 
 12 
Methods 13 
Study design 14 
A prospective, assessor-blinded, parallel group (1:1 allocation ratio) randomized controlled 15 
trial. Ethical approval was gained from the ethical review committee for research in humans, 16 
Faculty of Medicine, Chiang Mai University (#349/2012). The study was conducted in 17 
accordance with the Declaration of Helsinki. All participants provided written informed 18 
consent. (ClinicalTrial.gov NCT01736774).  19 
 20 
Participants  21 
Participants were recruited both from the headache clinic at Maharaj University Hospital and 22 
from the local community by advertising on local radio, in newspapers and flyers. A 23 
neurologist from the headache clinic screened and diagnosed potential participants from both 24 
sources. To be eligible for the study, participants were to be aged between 50-75 years, have 25 
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recurrent headaches diagnosed as either migraine, tension-type, cervicogenic or mixed 1 
headache with associated neck pain and CMD (restriction in active range of cervical motion in 2 
extension and rotation and palpable upper cervical joint dysfunction) [6]. Headache frequency 3 
had to be at least one per week over the past year, neck ≥ 3 on a 0-10 visual analogue scale 4 
(VAS) and neck disability ≥ 10 out of 100 as measured by the Neck Disability Index (NDI). 5 
Exclusion criteria were: headache diagnosed as temporal arteritis, trigeminal neuralgia, cluster 6 
headache, chronic paroxysmal hemicrania/hemicranias continua; temporomandibular disorders; 7 
neurological disorders (e.g. Parkinson disease, stroke); cognitive disturbance; previous serious 8 
head and neck trauma; any condition that contraindicated cervical mobilization; or receipt of 9 
physiotherapy treatment for headache during the past 12 months.  10 
 11 
A research assistant conducted a preliminary screening telephone interview with participants 12 
responding to advertisements. For those provisionally eligible for the trial, appointments were 13 
made with the trial neurologist and an experienced physiotherapist. The neurologist examined 14 
all potential participants (recruited from advertisements or the headache clinic) and assigned a 15 
headache diagnosis (migraine, tension-type, cervicogenic, mixed headache or other headache 16 
type) according to the criteria of the International Headache Society (IHS) [11] or for 17 
cervicogenic headache, the criteria of the Cervicogenic Headache International Study Group 18 
[12]. The physiotherapist, blinded to the neurologist’s diagnosis, performed a physical 19 
examination of the neck to identify the presence or not of CMD and make the clinical rating of 20 
greater, lesser or no CMD [6]. This included assessment of range of movement and a manual 21 
examination of the cervical segments [13, 14]. The participants rated any pain provoked on 22 
palpation on a numerical rating scale (NRS) and the physiotherapist rated the perceived tissue 23 
resistance to the manual palpation as normal, slight, moderate, or marked resistance. A joint 24 
was classified as symptomatic if pain provoked by manual examination was >2/10 in 25 
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combination with the physiotherapist’s rating of moderately or markedly abnormal tissue 1 
compliance [15]. A participant was judged to have greater CMD if they had at least 2 levels of 2 
symptomatic joint dysfunction and displayed restricted range of cervical motion in extension 3 
and rotation. If musculoskeletal dysfunction was present, but rated to lesser degree, the 4 
participant was assigned to lesser CMD. If manual examination and range of movement were 5 
painfree, a participant was assigned to have no CMD. On the basis of the neurologist’s and 6 
physiotherapist’s assessments, participants were either invited to participate or were judged 7 
ineligible.  8 
 9 
Randomization and masking 10 
Randomization was undertaken by an independent research assistant, not otherwise involved in 11 
the trial. Randomization was by computer generated permuted blocks with a block size of four, 12 
stratified by greater or lesser CMD, to ensure similar dysfunction between groups. Allocation 13 
was concealed in sequentially numbered, sealed, opaque envelopes. The envelopes were 14 
opened by the research assistant allocating patients to the respective intervention. 15 
Physiotherapists were not blinded to the treatment being provided but were blinded to 16 
participants’ headache diagnosis. Blinded assessors collected all baseline and follow-up 17 
physical measures and entered questionnaire data. 18 
 19 
Interventions 20 
Physiotherapy: The intervention was delivered by two physiotherapists, experienced in the trial 21 
treatments. The treatment period was 10-weeks and commenced within one week of baseline 22 
assessment. Participants received 14 individual treatment sessions (2 visits per week for the 23 
first 4 weeks followed by one visit per week for the last 6 weeks). Each treatment session 24 
lasted approximately 45 minutes and included a combination of cervical mobilization and a 25 
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therapeutic exercise program, a regime which has proven successful in previous trials of 1 
headache management [7, 16]. The cervical mobilization consisted of low-velocity techniques 2 
[17]. The therapeutic exercise program was a low load exercise for the craniocervical flexor [7, 3 
18] and axioscapular muscles [19] and postural correction exercises [18, 20]. Muscle 4 
lengthening exercise could also be given to address any muscle tightness. The elements of the 5 
treatment were delivered at the discretion of the physiotherapist, based on the initial and 6 
progressive assessment of participant’s cervical joint and muscular dysfunction. The exercise 7 
programs were progressed gradually from non-functional to functional performance. 8 
Participants were instructed to practice their exercise once daily (10-20 minutes) during the 9 
intervention period, without aggravating pain. Participants completed an exercise diary to 10 
monitor compliance and record adverse events. Significant adverse effects were defined as any 11 
increases in pain (headache or neck pain), loss of neck motion, and/or loss of function as a 12 
result of the intervention. 13 
 14 
Usual care: Participants randomly allocated to the usual care group were asked to continue 15 
with their medication and were able to receive other care as they thought appropriate except for 16 
physiotherapy treatment. To avoid the risks of behavioral change, the usual care group received 17 
only neutral information. No extra information about their condition or treatment advice was 18 
provided. Any treatments received and adverse events during the 10 week intervention period 19 
were recorded in a diary log-book. 20 
 21 
Measurements 22 
A baseline questionnaire was administered to document participant demographics, headache 23 
history and any treatment received to date. A daily headache diary was used to record headache 24 
measures (frequency, intensity and duration) one week before baseline and follow-up 25 
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assessments. Primary and secondary outcome measures were recorded at baseline, 11 weeks, 6 1 
months and 9 months after randomization. The exception was cervical range of motion, 2 
participants’ perception of treatment benefit and quality of life which were measured at 3 
baseline, 11 weeks and 9 months.  4 
 5 
Primary outcome measure 6 
Headache frequency was the primary outcome measure [21]. The number of headache days 7 
was recorded in a daily headache diary one week before the respective assessment dates and 8 
the total number of headache days per week was used for analysis.  9 
 10 
Secondary outcome measures 11 
Other headache measures: Headache intensity and duration were measured with a daily 12 
headache diary. Participants reported daily headache pain intensity using a 0-10 NRS and the 13 
number of hours of headache for each day in the past week. Means scores across the 7-day 14 
period were used for analysis.  15 
 16 
Neck pain and disability measures: Neck pain intensity was measured using a VAS. The 17 
participants indicated their average neck pain intensity over the past week by marking a 18 
100mm line. Likewise a weekly measure was recorded of neck related disability using the 19 
Neck Disability Index-Thai version (NDI-TH) [22]. The NDI-TH has 10 sections and each has 20 
a five point Likert response (total score, 50). A higher score indicates greater perceived 21 
disability [23].  22 
 23 
Cervical range of motion: A cervical range of motion (CROM) device was used to measure 24 
flexion/extension, left-right rotation, left-right lateral flexion and left-right upper cervical 25 
rotation [24]. The CROM is a reliable tool to assess cervical range of motion [25]. 26 
Page 9 of 35
10 
 
 1 
Quality of life: Health-related quality of life was assessed using the SF-36-Thai version [26], 2 
which contains 36 questions covering eight domains of health. The eight domains were 3 
summed into a physical component summary score (PCS) and a mental component summary 4 
score (MCS) and then expressed as a percentage, with higher score representing better health.  5 
 6 
Participant’s perception of treatment benefit: Perceived benefit was measured with a 0-10 7 
scale (0 = no benefit and 10 = maximum benefit).  8 
 9 
Medication: Participants recorded the type and dose of all medications taken in a medication 10 
diary for a one-week baseline period and for one week prior to follow-up points. Medication 11 
consumption was converted into defined daily dose (DDD) unit by multiplying the units 12 
dispensed field with the DDD conversion [27]. For example, the DDD for paracetamol is 3g 13 
and the strength of one tablet is 500mg. Each 500mg tablet is equivalent to 0.17 DDD. 14 
Multiplying the quantity (6 tablets) by a conversion factor of 0.17 equals a consumption of 15 
1.02 DDDs. The sum of DDDs of all medications consumed in one week was calculated and 16 
used for analysis. 17 
 18 
Procedure 19 
Participants attended the Department of Physiotherapy, Chiang Mai University for baseline 20 
assessment. They were randomly allocated to either the 10 week physiotherapy program or 21 
usual care. All participants were reassessed at 11 weeks (at the university), 6 months (postal 22 
questionnaires) and 9 months (at the university). All participants were asked to complete a 23 
daily headache diary for the week before each re-assessment date. They noted the presence or 24 
not of headache on each day, its intensity and duration and also whether it was their familiar 25 
headache or a different headache, for example, associated with a cold or flu. Participants 26 
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receiving the physiotherapy intervention were asked to refrain from seeking other treatment for 1 
their headache during the trial. Due to ethical considerations, usual medication was not 2 
withheld from any participant, regardless of group. Participants recorded the type and dose of 3 
all medications taken in a medication diary. Reminder telephone calls were used to help to 4 
maintain a high retention rate, including two calls to participants in the usual care group during 5 
the 10 week intervention. 6 
 7 
Sample size calculation 8 
Sample size was based on the primary outcome of headache days per week. According to the 9 
IHS guidelines [21], a 50% reduction in headache days per week is considered a clinically 10 
significant difference. A sample size of 58 participants was required for the study based on a 11 
priori power analysis with a power of 0.8 and an alpha of 0.05. Assuming a dropout rate of 12 
10%, 64 participants (32 per group) was the target sample size for enrollment.  13 
 14 
Statistical analysis 15 
Independent t-tests and Chi-square analyses were performed to compare demographic 16 
characteristics between participants and people who refused to participate. Imputation method 17 
was used for handling missing data, which occurred in one participant in the physiotherapy 18 
group for cervical movement at the 9-month follow-up due to lack of time. Two analytic 19 
approaches (the last observation carried forward and likewise deletion) were applied in a 20 
preliminarily analysis to inform the handling of single missing data at random. Similar 21 
outcomes were obtained. Missing data imputation by the last observation carried forward was 22 
chosen to minimize the number of the participant eliminated from analysis. The change from 23 
baseline (mean and 95% confidence interval) for each pairwise between-group comparison and 24 
within groups was estimated using a linear mixed model with Bonferroni post-hoc adjustment 25 
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and the baseline value was used as a covariate. A partial eta squared (η2) was calculated to 1 
determine effect size. An effect size of 0.01 was regarded as small, 0.06 as medium, and 0.14 2 
as large [28]. Dichotomous responder analysis was conducted to evaluate whether 3 
improvement in headache frequency was clinically significant (≥ 50% reduction in the number 4 
of headache days post-treatment and at follow-ups). The results are presented as relative risks 5 
with 95% confidence interval.  6 
 7 
Subgroup analyses were explored to determine whether any effects of neck treatment differed 8 
according to headache diagnosis (cervicogenic or non-cervicogenic) or CMD (greater or 9 
lesser). Analyses were performed based on tests for the 3-way interaction between each 10 
subgroup (headache diagnosis or musculoskeletal dysfunction), treatment allocation 11 
(physiotherapy and usual care), and time (11 weeks, 6 months and 9 months). No interaction 12 
would indicate similar treatment effects in subgroups over time [29]. Differences in 13 
demographic and baseline data between groups (cervicogenic versus non-cervicogenic, and 14 
greater versus lesser CMD) were initially tested using independent-t test and chi-square. 15 
Significant differences were evident in age and baseline data (headache frequency, intensity 16 
and duration, and neck pain intensity and disability) between the groups. Age and baseline data 17 
were then adjusted in the 3-way interaction analyses. Subgroup analyses were confined to the 18 
primary outcome (headache frequency) and key secondary outcomes (headache intensity and 19 
duration, and neck pain and disability).  20 
 21 
Statistical significance was set at p < 0.05. Data were analyzed using SPSS Statistics version 22 
18 (SPSS Co., Ltd. Bangkok, Thailand). 23 
 24 
Results 25 
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Participant characteristics 1 
The study commenced in January 2013 and was completed in July 2015. Figure 1 presents the 2 
flow diagram of participant recruitment and retention. Sixty-five participants entered the study 3 
and none were lost to follow-up for the primary outcome. Data for cervical movement was not 4 
collected from one participant (3%) in the physiotherapy group at the 9-month follow-up. 5 
Demographic characteristics between participants and persons who refused to join the trial are 6 
presented in Table 1. Fifteen people who refused passed the preliminary screening but declined 7 
diagnostic and physical assessments for headache. No significant differences in demographic 8 
characteristics were found between participants and persons who refused to participate (p > 9 
0.05) 10 
 11 
Interventions 12 
All participants in the physiotherapy group completed 14 treatment sessions over 10 weeks. 13 
Analysis of exercise diaries indicated that participants practiced exercises on 63.4 (SD, 8.7) of 14 
70 days of the treatment period. Three participants in the usual care group reported using balm 15 
to reduce pain, six received massage, and one received acupuncture. Four participants in the 16 
treatment group reported discomfort around their neck after the first treatment and the 17 
discomfort disappeared within 24 hours. No significant adverse effects were reported in either 18 
group.  19 
 20 
Primary outcome 21 
Descriptive data for the primary outcome from baseline to each follow period are summarized 22 
in Table 2 and results of analysis of changes between and within-groups are presented in Table 23 
3. The participants receiving physiotherapy had significantly reduced headache frequency 24 
immediately after treatment (week 11) compared with usual care. The difference remained 25 
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significant at 6- and 9-month follow-ups. Effect size estimates indicated a large effect for 1 
physiotherapy treatment on headache frequency (Table 4). The effectiveness of the 2 
intervention was also investigated by examining the number of participants who responded to 3 
treatment. At all follow up points, the physiotherapy group had a significantly higher 4 
proportion of participants who experienced greater than 50% reduction in headache frequency 5 
than the usual care group and 60% were headache free at 9-months (Table 5). 6 
 7 
Secondary outcomes 8 
Descriptive data for secondary outcomes at each time point are summarized in Table 2. Results 9 
of analysis of changes between and within-groups are presented in Table 3. There were 10 
significant reductions in headache intensity and duration, neck pain and disability measures 11 
(VAS and NDI-TH) immediately after treatment (11 weeks), and at 6- and 9-month time points 12 
compared to the usual care group. Significant differences between groups were recorded at the 13 
post-treatment (11 weeks) and the 9 month follow-up, for cervical ranges of motion, quality of 14 
life measures and participant’s perception of treatment benefit. The exception was upper 15 
cervical rotation at the 9 month follow up. There was a positive trend for reduced medication 16 
use in the physiotherapy group, but differences from the usual care group were not significant.  17 
 18 
Subgroup analyses 19 
Descriptive data for subgroup analyses are present in Tables 6 and 7. Cervicogenic headache 20 
was the most common diagnosis (69.7%, physiotherapy group; 65.6%, usual care group) and, 21 
for analysis, all other headaches were pooled into a non-cervicogenic headache group. 22 
Approximately 75% of participants in each group were rated with greater CMD. After 23 
adjusting for age and baseline data, there were no interactions between subgroups (headache 24 
diagnosis and CMD) and treatment allocation over time for the primary outcome and 25 
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secondary outcomes (headache intensity and duration; neck pain and disability measures (p > 1 
0.05). The exception was headache duration, where a significant interaction was found between 2 
subgroup of CMD, treatment allocation and time (p = 0.012). Bonferroni post-hoc results 3 
showed that post-treatment (11 weeks), participants with greater CMD in the physiotherapy 4 
group had significantly greater improvement in headache duration than those with lesser CMD 5 
(mean difference = 3.3 hours/day, 95% CI = 0.3 to 6.3, p = 0.031).  6 
 7 
Discussion 8 
In older age, primary headaches as migraine become less typical, secondary headaches increase 9 
in frequency and neck pain with headache is prevalent [2, 4, 5]. We included participants with 10 
diagnoses of migraine, tension-type, mixed or cervicogenic headache. Nevertheless, our 11 
primary inclusion criteria were the presence of neck pain and CMD for which there is evidence 12 
of effectiveness of the physiotherapy interventions used in this study [7, 16]. This study 13 
demonstrated that a treatment program consisting of cervical mobilization and therapeutic 14 
exercise significantly reduced headache frequency in seniors with recurrent headache 15 
compared with usual care. Greater improvement also occurred in headache intensity and 16 
duration, neck pain intensity and disability, range of motion and quality of life. Participants 17 
perceived treatment as beneficial. Additionally, there was a trend for reduction in average daily 18 
medication dose in the physiotherapy group. Treatment effects were evident immediately after 19 
treatment and were maintained in the long-term. No noteworthy adverse effects were reported. 20 
Taken together, the results indicate that conservative physiotherapy management of the neck is 21 
a suitable intervention for seniors with recurrent headache associated with neck pain and CMD.  22 
 23 
Estimates of effect size were large for most headache symptoms at week 11, and at 6 and 9 24 
months. In clinical terms, treating the neck was approximately twice as effective as usual care 25 
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in achieving a clinically relevant reduction in headache frequency (>50% reduction) and 1 
approximately 60% reported complete relief from headache with neck treatment compared to 2 
28% in the usual care group at the long term follow-up. Notably, two-thirds of seniors were 3 
diagnosed with cervicogenic headache, and of the remainder, migraine was diagnosed most 4 
commonly (60%). This may reflect our inclusion criteria of the presence of neck pain and 5 
CMD and the purported greater prevalence of cervicogenic headache after the age of 50 [30, 6 
31]. Additionally, with strict eligibility criteria to maintain internal validity, only one-third of 7 
seniors with headache were included in the trial. Thus the trial findings may have limited 8 
generalizability.  9 
 10 
Other studies have also demonstrated effectiveness of cervical mobilization and therapeutic 11 
exercise for patients with cervicogenic headache [7, 8]. Interestingly, the sub-group analyses 12 
revealed that our clinical estimate of magnitude of CMD (lesser or greater) did not impact on 13 
the chance of a favorable outcome and notably there was no difference in treatment effects 14 
according to headache classification (cervicogenic or non-cervicogenic). We make no general 15 
claim that treatment of the neck is efficacious for non-cervicogenic headaches as migraine. 16 
Neck pain may be an expression of the centrally sensitized trigemino-cervical nucleus [32] 17 
rather than signal a local cervical disorder. Indeed, a systematic review in 2011 concluded that 18 
there was no support for the use of spinal manipulations in treatment for migraine [33]. 19 
Likewise, a recent study investigating the effect on migraine of medication alone or combined 20 
with physiotherapy (cervical mobilization and muscle stretching) found marginal but no 21 
significant additional benefit of physiotherapy on headache frequency [34].  22 
 23 
These findings seem at variance to the results of our study where the diagnosis of migraine in 24 
some participants did not mitigate against benefit from the physiotherapy intervention. 25 
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Interestingly in the previous migraine trial [34], there was no improvement in cervical range of 1 
motion. An improvement could be expected with such treatment if any neck pain was related to 2 
CMD. Our participants, receiving similar physiotherapy interventions showed improvements in 3 
range of movement in excess of the minimal clinically important difference (6.5 in any 4 
direction) [25] and achieved clinically meaningful change (≥20%) in the NDI score [35]. The 5 
difference in our cohort was that, regardless of headache diagnosis, they were required to have 6 
CMD in association with headache and any associated neck pain. The outcomes of our trial 7 
would suggest that this CMD played an active role in headache. Our results provide evidence 8 
that cervicogenic headache in seniors is responsive to local treatment of the neck. The results 9 
also suggest that neck pain associated with CMD could be an additional peripheral source of 10 
nociception in primary headache in seniors, which is responsive to local treatment of the neck. 11 
The study highlights the importance of offering a pragmatic approach for management of 12 
seniors who experience recurrent headache in association with neck pain and CMD.  13 
 14 
There are limitations to this trial. Blinding of the treating physiotherapists and participants was 15 
not possible. Performance bias, that is, participants allocated to the treatment group received 16 
more attention during the 10 week intervention period, may contribute to a greater chance of 17 
positive outcomes. Participant selection was based on classification criteria for migraine, 18 
tension-type [11] and cervicogenic headache [12], but diagnostic nerve or joint blocks to 19 
confirm cervicogenic headache could not be justified for our cohort of seniors. The headache 20 
diary entries were not electronically time-stamped. Some participants may have backfilled their 21 
diaries, resulting in recall issues. The sample size was not justified for the subgroup analyses. 22 
The subgroup analyses represented a relatively small number of participants and results should 23 
be interpreted with some caution, although results were non-significant.  24 
 25 
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Conclusions 1 
A program of low-velocity cervical mobilization and therapeutic exercise is effective for 2 
seniors with recurrent headache when associated with neck pain and CMD, regardless of 3 
headache classification. Given the heterogeneity of headache in this age group, concerns about 4 
medication overuse and drug interactions, management of any associated painful CMD might 5 
contribute positively to a multifactorial headache intervention strategy for this group.    6 
 7 
Conflict of Interest Statement 8 
There is no conflict of interest. 9 
 10 
  11 
Page 18 of 35
19 
 
References 1 
[1]. Haan J, Hollander J, Ferrari M. Migraine in the elderly: a review. Cephalalgia 2 
2007;27:97-106. 3 
[2]. Kelman L. Migraine changes with age: IMPACT on migraine classification. Headache 4 
2006;46:1161-71. 5 
[3]. Ozge A, Uluduz D, Selekler M, et al. Gender differences in older adults with chronic 6 
migraine in Turkey. Geriatr Gerontol Int 2015;15:652-8. 7 
[4]. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of 8 
migraine. Neurology 2006;67:246-51. 9 
[5]. Hershey LA, Bednarczyk EM. Treatment of headache in the elderly. Curr Treat Options 10 
Neurol 2013;15:56-62. 11 
[6]. Uthaikhup S, Sterling M, Jull G. Cervical musculoskeletal impairment is common in 12 
elders with headache. Man Ther 2009;14:636-41. 13 
[7]. Jull G, Trott P, Potter H, et al. A randomized controlled trial of exercise and manipulative 14 
therapy for cervicogenic headache. Spine 2002;27:1835-43. 15 
[8]. Ylinen J, Nikander R, Nykanen M, Kautiainen H, Hakkinen A. Effect of neck exercises 16 
on cervicogenic headache: a randomized controlled trial. J Rehabil Med 2010;42:344-9. 17 
[9]. Braunstein D, Donnet A, Pradel V, et al. Triptans use and overuse: A 18 
pharmacoepidemiology study from the French health insurance system database covering 19 
4.1 million people. Cephalalgia 2015;35:1172-80. 20 
[10]. Prencipe M, Casini AR, Ferretri C, et al. Prevalence of headache in an elderly population: 21 
attack frequency, disability, and use of medication. J Neurol  Neurosurg Psychiatry 22 
2001;70:377-81. 23 
[11]. International Headache Society. The International Classification of Headache Disorders 24 
2nd edition. Cephalalgia 2004;24 (Suppl 1):S1-151. 25 
Page 19 of 35
20 
 
[12]. Sjaastad O, Fredriksen TA, Pfaffenrath V. Cervicogenic headache: Diagnostic criteria. 1 
Headache 1998;38:442-5. 2 
[13]. Jull G, Bogduk N, Marsland A. The Accuracy of Manual Diagnosis for Cervical 3 
Zygapophysial Joint Pain Syndromes. Med J Aust 1988;148:233-6. 4 
[14]. Schneider GM, Jull G, Thomas K, et al. Derivation of a clinical decision guide in the 5 
diagnosis of cervical facet joint pain. Arch Phys Med Rehabil 2014;95:1695-701. 6 
[15]. Jull G, Amiri M, Bullock-Saxton J, Darnell R, Lander C. Cervical musculoskeletal 7 
impairment in frequent intermittent headache. Part 1: Subjects with single headaches. 8 
Cephalalgia 2007;27:793-802. 9 
[16]. van Ettekoven H, Lucas C. Efficacy of physiotherapy including a craniocervical training 10 
programme for tension-type headache; a randomized clinical trial. Cephalalgia 11 
2006;26:983-91. 12 
[17]. Maitland GD, Hengeveld E, Banks K, English K. Maitland's vertebral manipulation. 6th, 13 
ed. Edinburgh, New York: Butterworth-Heinemann; 2005. 14 
[18]. Jull G, Sterling M, Falla D, Treleaven J, O'Leary S. Whiplash, headache, and neck pain. 15 
Edinburgh: Churchill Livingstone; 2008. 16 
[19]. Wegner S, Jull G, O'Leary S, Johnston V. The effect of a scapular postural correction 17 
strategy on trapezius activity in patients with neck pain. Man Ther 2010;15:562-6. 18 
[20]. Caneiro JP, O'Sullivan P, Burnett A, et al. The influence of different sitting postures on 19 
head/neck posture and muscle activity. Man Ther 2010;15:54-60. 20 
[21]. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in 21 
migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6-38. 22 
[22]. Uthaikhup S, Paungmali A, Pirunsan U. Validation of Thai versions of the Neck 23 
Disability Index and Neck Pain and Disability Scale in patients with neck pain. Spine 24 
2011;36:1415-21. 25 
Page 20 of 35
21 
 
[23]. Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J 1 
Manipulative Physiol Ther 1991;14:409-15. 2 
[24]. Hall TM, Robinson KW, Fujinawa O, Akasaka K, Pyne EA. Intertester reliability and 3 
diagnostic validity of the cervical flexion-rotation test. J Manipulative Physiol Ther 4 
2008;31:293-300. 5 
[25]. Audette I, Dumas JP, Cote JN, De Serres SJ. Validity and between-day reliability of the 6 
cervical range of motion (CROM) device. J Orthop Sports Phys Ther 2010;40:318-23. 7 
[26]. Lim LL, Seubsman SA, Sleigh A. Thai SF-36 health survey: tests of data quality, scaling 8 
assumptions, reliability and validity in healthy men and women. Health and quality of life 9 
outcomes. 2008;6:52 doi: 10.1186/1477-7525-6-52. 10 
[27]. WHO Collaborating Centre for Drug Statistics and Methodology: Guidelines for ATC 11 
classification and DDD assignment. Oslo, Norway2013. 12 
[28]. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Routledge 13 
Academic; 1988. 14 
[29]. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of 15 
baseline data in clinical trials. Lancet 2000;355:1064-9. 16 
[30]. Biondi DM, Saper JR. Geriatric headache: How to make the diagnosis and manage the 17 
pain. Geriatric 2000;55:40-50. 18 
[31]. Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy. 19 
Clin Exp Rheumatol 2000;18 (Suppl 19):S59-S64. 20 
[32]. Bartsch T. Migraine and the neck: new insights from basic data. Curr Pain Headache Rep 21 
2005;9:191-6. 22 
[33]. Posadzki P, Ernst E. Spinal manipulations for the treatment of migraine: a systematic 23 
review of randomized clinical trials. Cephalalgia 2011;31:964-70. 24 
Page 21 of 35
22 
 
[34]. Bevilaqua-Grossi D, Goncalves MC, Carvalho GF, et al. Additional effects of a physical 1 
therapy protocol on headache frequency, pressure pain threshold, and improvement 2 
perception in patients with migraine and associated neck pain: a randomized clinical trial. 3 
Arch Phys Med Rehabil 2015 doi: 10.1016/j.apmr.2015.12.006. 4 
[35]. Young BA, Walker MJ, Strunce JB, Boyles RE, Whitman JM, Childs JD. 5 
Responsiveness of the Neck Disability Index in patients with mechanical neck disorders. 6 
Spine J 2009;9:802-8. 7 
 8 
 9 
Page 22 of 35
23 
 
Figure 1 Flow diagram of the trial  
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Table 1 Demographic characteristics between participants and persons who refused to 
participate 
Variables Participants Refusers 
(n =24) 
p-value** 
Physiotherapy  
(n = 33) 
Usual care  
(n = 32) 
Total 
(n =65) 
Age (yrs), mean (SEM) 59.9 (1.2) 61.6 (0.9) 60.7 (0.7) 63.2 (1.4) 0.10 
Gender (female), % 81.8  90.6 86.2 87.5 0.87 
BMI (kg/m
2
), mean (SEM) 24.1 (0.7) 25.8 (0.6)  24.9 (0.5) 26.6 (0.9)* 0.22 
Employment status, n 
     Retired 
     Full time employment 
     Self-employed      
     Housewife 
 
7 
9 
10 
7 
 
8 
3 
16 
5 
  
- 
- 
- 
- 
 
- 
- 
- 
- 
History of headache (yrs), 
mean (SEM) 
8.5 (1.6)  6.3 (1.5) 7.4 (1.1) 3.9 (1.1) 0.07 
Headache diagnosis (type), n 
     Migraine 
     Tension-type headache 
     Cervicogenic headache 
     Mixed headache 
 
6 
2 
23 
2 
 
7 
0 
21 
4 
 
13 
2 
44 
6 
 
1* 
0 
8* 
0 
0.58 
 
CMD (greater), % 75.8 75.0 75.4 55.6* 0.21 
CMD = cervical musculoskeletal impairment 
* Total number of refusers (n = 9)  
** Compared between refusers and total participants  
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Table 2 Primary and secondary outcomes for each intervention group. Means and (standard deviations) are presented. 
 
 
Outcome variables 
Physiotherapy 
(n = 33) 
 Usual care 
(n = 32) 
Baseline 11 weeks  6 months  9 months   Baseline 11 weeks  6 months  9 months  
Primary outcome 
Headache frequency (days/week)  
 
4.3 (0.4) 
 
1.7 (0.4) 
 
1.5 (0.4) 
 
0.8 (0.2) 
  
3.9 (0.4) 
 
3.0 (0.4) 
 
2.9 (0.5) 
 
2.9 (0.5) 
 
Secondary outcome 
Headache intensity (0-10 NRS) 
 
 
4.5 (0.3) 
 
 
1.4 (0.3) 
 
 
1.5 (0.3) 
 
 
1.2 (0.3) 
  
 
4.7 (0.4) 
 
 
4.8 (0.4) 
 
 
4.0 (0.5) 
 
 
3.6 (0.6) 
Headache duration (hours/day) 5.2 (1.0) 2.2 (0.6) 2.7 (0.9) 1.9 (0.9)  4.8 (1.0) 4.7 (1.0) 4.7 (1.1) 5.60 (1.2) 
Neck pain intensity (0-10 VAS) 5.1 (0.3) 1.7 (0.2) 1.4 (0.3) 1.5 (0.3)  5.4 (0.2) 4.73 (0.2) 4.8 (0.3) 4.80 (0.3) 
Neck pain and disability (%) 30.9 (1.6) 10.1 (1.2) 9.2 (1.3) 8.4 (1.3)  27.7 (1.7) 26.4 (1.5) 24.6 (1.6) 23.83 (1.8) 
Cervical range of motion (degrees) 
      Flexion-extension  
 
105.0 (1.6) 
 
115.6 (1.9) 
 
N/A 
 
113.0 (1.7) 
  
105.5 (1.8) 
 
105.9 (1.6) 
 
N/A 
 
107.23 (2.5) 
      Lateral flexion (right-left)  58.5 (2.0) 66.3 (2.1) N/A 68.1 (2.1)  59.7 (1.6) 59.9 (1.5) N/A 64.6 (1.7) 
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Outcome variables 
Physiotherapy 
(n = 33) 
 Usual care 
(n = 32) 
Baseline 11 weeks  6 months  9 months   Baseline 11 weeks  6 months  9 months  
      Rotation (right-left)  115.2 (2.2) 125.0 (1.9) N/A 125.2 (2.1)  115.1 (2.0) 115.5 (2.4) N/A 117.9 (1.9) 
      Upper cervical rotation  47.7 (1.1) 53.3 (1.0) N/A 53.6 (1.2)  49.0 (0.9) 51.0 (1.0) N/A 51.7 (1.0) 
Quality of life SF 36 (%) 
      Physical component summary  
 
54.5 (2.6) 
 
78.4 (2.0) 
 
N/A 
 
77.7 (2.1) 
  
55.7 (2.8) 
 
53.6 (2.7) 
 
N/A 
 
56.6 (2.2) 
      Mental component summary  65.6 (2.8) 83.7 (1.9) N/A 79.4 (2.4)  68.8 (2.7) 62.1 (3.0) N/A 63.2 (3.0) 
Treatment benefit (0-10 VAS)    4.5 (0.6) 9.3 (0.2) N/A 9.4 (0.2)  3.6 (0.6) 6.3 (0.5) N/A 6.7 (0.4) 
Medication (DDD per week)    2.0 (1.5) 0.04 (0.02) 0.05 (0.04) 0.03 (0.02)  0.7 (0.3) 1.2 (0.8) 1.0 (0.8) 1.3 (0.8) 
Data are expressed in mean (standard error), NRS = Numerical Rating Scale, VAS = Visual Analogue Scale, DDD = Defined Daily Dose 
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Table 3 Means (standard error) for within group changes and adjusted mean (95% confidence interval) for differences in between-group change 
for all outcome variables 
 
Outcome variables 
 
Time frame 
Change within groups*  Changes between-groups** 
Physiotherapy p-value    Usual care p-value     Difference p-value 
Primary outcome 
Headache frequency (days/week) 
 
Baseline-week 11 
 
2.6 (0.3) 
 
<0.001 
 
0.9 (0.4) 
 
0.052 
  
-1.6 (-2.5 to -0.6) 
 
0.001 
Baseline-6 months  2.8 (0.4) <0.001 1.0 (0.4) 0.041  -1.7 (-2.6 to -0.8) 0.001 
Baseline-9 months 3.5 (0.3) <0.001 1.0 (0.3) 0.023  -2.4 (-3.2 to -1.5) <0.001 
Secondary outcomes 
Headache intensity (0-10 NRS) 
 
Baseline-week 11 
 
3.1 (0.3) 
 
<0.001 
 
-0.1 (0.3) 
 
1.00 
  
-3.3 (-4.1 to -2.4) 
 
<0.001 
Baseline-6 months  2.9 (0.4) <0.001 0.7 (0.4) 0.49  -2.3 (-3.4 to -1.3) <0.001 
Baseline-9 months 3.2 (0.5) <0.001 1.1 (0.5) 0.32  -2.4 (-3.6 to -1.1) <0.001 
Headache duration (hours/day) Baseline-week 11 3.0 (0.8) 0.005 0.2 (0.9) 1.00  -2.6 (-4.4 to -0.7) 0.007 
Baseline-6 months  2.5 (0.8) 0.020 0.2 (0.8) 1.00  -2.2 (-4.4 to -0.04) 0.046 
Baseline-9 months 3.3 (1.2) 0.033 -0.8 (1.2) 1.00  -3.8 (-6.6 to -1.0) 0.008 
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Outcome variables 
 
Time frame 
Change within groups*  Changes between-groups** 
Physiotherapy p-value    Usual care p-value     Difference p-value 
Neck pain intensity (0-10 VAS) Baseline-week 11 3.5 (0.3) <0.001 0.7 (0.3) 0.18  -3.0 (-3.7 to -2.4) <0.001 
Baseline-6 months  3.7 (0.3) <0.001 0.6 (0.3) 0.58  -3.3 (-4.1 to -2.6) <0.001 
Baseline-9 months 3.7 (0.3) <0.001 0.6 (0.3) 0.59  -3.3 (-4.1 to -2.4) <0.001 
Neck pain and disability (%) Baseline-week 11 20.8 (1.5) <0.001 1.3 (1.5) 1.00  -17.7 (-21.1 to -14.2) <0.001 
Baseline-6 months  21.7 (1.7) <0.001 3.1 (1.7) 0.49  -16.5 (-20.4 to -12.6) <0.001 
Baseline-9 months 22.5 (1.8) <0.001 3.9 (1.9) 0.26  -16.4 (-20.6 to -12.2) <0.001 
Cervical range of motion 
(degrees) 
    Flexion-extension  
 
 
Baseline-week 11 
 
 
-10.6 (1.5) 
 
 
<0.001 
 
 
-0.5 (1.6) 
 
 
1.00 
  
 
10.0 (6.0 to 14.0) 
 
 
<0.001 
Baseline-9 months -8.1 (1.7) <0.001 -1.8 (1.7) 0.91  6.19 (1.5 to 10.9) 0.010 
    Lateral flexion (right-left)  Baseline-week 11 -7.9 (1.6) <0.001 -0.3 (1.7) 1.00  7.1 (3.0 to 11.3) 0.001 
Baseline-9 months -9.6 (1.6) <0.001 -4.9 (1.6) 0.01  4.3 (0.2 to 8.5) 0.043 
    Rotation (right-left)  Baseline-week 11 -9.8 (1.8) <0.001 -0.3 (1.8) 1.00  9.5 (4.8 to 14.2) <0.001 
Baseline-9 months -10.0 (1.9) <0.001 -2.8 (1.9) 0.48  7.3 (2.6 to 12.0) 0.003 
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Outcome variables 
 
Time frame 
Change within groups*  Changes between-groups** 
Physiotherapy p-value    Usual care p-value     Difference p-value 
    Upper cervical rotation 
     
Baseline-week 11 -5.6 (1.2) <0.001 -1.9 (1.2) 0.30  2.8 (0.1 to 5.5) 0.045 
Baseline-9 months -5.9 (1.2) <0.001 -2.7 (1.2) 0.10  2.4 (-0.6 to 5.4) 0.11 
Quality of life SF 36 (%) 
    Physical component summary  
 
Baseline-week 11 
 
-24.0 (2.7) 
 
<0.001 
 
2.1 (2.7) 
 
1.00 
  
25.3 (19.2 to 31.4) 
 
<0.001 
Baseline-9 months -23.3 (2.6) <0.001 -0.9 (2.7) 1.00  21.6 (16.0 to 27.2) <0.001 
    Mental component summary  Baseline-week 11 -18.1 (2.3) <0.001 6.7 (2.4) 0.019  23.4 (17.6 to 29.2) <0.001 
Baseline-9 months -13.8 (2.5) <0.001 5.6 (2.6) 0.10  17.9 (11.6 to 24.2) <0.001 
Treatment benefit (0-10 VAS)    Baseline-week 11 -4.8 (0.7) <0.001 -2.8 (0.7) 0.001  3.1 (2.1 to 4.1) <0.001 
Baseline-9 months -4.9 (0.7) <0.001 -3.1 (0.7) <0.001  2.8 (2.0 to 3.6) <0.001 
Medication (DDD per week)    Baseline-week 11 2.0 (1.1) 0.56 -0.5 (1.2) 1.00  -1.3 (-2.8 to 0.3) 0.10 
Baseline-6 months 1.9 (1.2) 0.57 -0.3 (1.2) 1.00  -1.1 (-2.6 to 0.5) 0.17 
Baseline-9 months 2.0 (1.2) 0.56 -0.6 (1.2) 1.00  -1.4 (-3.0 to 0.1) 0.073 
** adjusted for baseline values 
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* For changes within groups, positive values denote improvement, except for cervical range of motion, SF 36 and treatment benefit where 
negative values denote improvement. 
** For differences in changes between-groups, positive values in cervical range of motion, SF 36 and treatment benefit, and negative values in 
the headache characteristics, neck pain intensity, neck disability and medication favor the first named group (physiotherapy) in the pairwise 
comparison. 
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Table 4 Effect size estimates for group differences  
 
Outcome 
Effect size (η2p) 
Baseline to after 
treatment 
Baseline to 6 month-
follow up 
Baseline to 9 month-
follow up 
Headache frequency 0.16 0.17 0.35 
Headache intensity 0.49 0.25 0.19 
Headache duration 0.11 0.06 0.11 
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Table 5 The number of participants (%) with a greater than 50% and 100% reduction in headache frequency at follow-ups compared to baseline 
 
Headache 
frequency 
50% reduction  
p-value 
 
Relative risk 
(95% confidence 
interval) 
 100% reduction  
p-value 
 
Relative risk 
(95% confidence 
interval) 
Physiotherapy  
n =33  
Usual care  
n =32  
 Physiotherapy  
n =33  
Usual care  
n =32  
11 weeks 
6 months 
9 months 
24 (72.7) 
27 (81.8) 
31 (93.9) 
13 (40.6) 
15 (46.9) 
14 (43.8) 
0.009 
0.003 
<0.001 
1.8 (1.1 to 2.9) 
1.8 (1.2 to 2.6)  
2.2 (1.4 to 3.2) 
 16 (48.5) 
15 (45.5) 
20 (60.6) 
2 (6.3) 
7 (21.7) 
9 (28.1) 
<0.001 
0.045 
0.008 
7.8 (1.9 to 31.1) 
2.1 (1.0 to 4.4) 
2.2 (1.2 to 4.0) 
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Table 6 Sub-group analyses based on cervicogenic or non-cervicogenic headache for the primary outcome and key secondary outcomes 
 
Outcome variables 
Physiotherapy Usual care p value for interaction  
treatment*sub-group* 
time  
Cervicogenic  
(n = 23) 
Non-cervicogenic 
(n = 10) 
Cervicogenic 
(n = 21) 
Non-cervicogenic 
(n = 11) 
Primary outcome                      
     Headache frequency (days/week)  
 
1.6 (0.6 to 2.5) 
 
1.6 (0.3 to 3.0) 
 
2.1 (1.0 to 3.1) 
 
4.0 (2.8 to 5.2) 
 
0.19 
Secondary outcome 
     Headache intensity (0-10 NRS) 
 
2.1 (1.1 to 3.0) 
 
1.5 (0.2 to 2.9) 
 
3.7 (2.6 to 4.7) 
 
4.7 (3.4 to 5.9) 
 
0.079 
     Headache duration (hours/day) 3.4 (1.3 to 5.5) 0.6 (-2.4 to 3.6) 4.2 (1.8 to 6.6) 6.5 (3.7 to 9.3) 0.87 
     Neck pain intensity (0-10 VAS) 1.8 (1.3 to 2.3) 1.1 (0.3 to 1.8) 4.6 (4.0 to 5.1) 5.1 (4.4 to 5.9) 0.45 
     Neck pain and disability (%) 10.2 (7.8 to 12.7) 4.6 (1.0 to 8.3) 25.0 (22.4 to 27.6) 27.0 (23.5 to 30.5) 0.23 
Value are estimated mean (95% confidence interval) after adjusting for baseline values and age 
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Table 7 Sub-group analyses based on greater or lesser musculoskeletal dysfunction for the primary outcome and key secondary outcomes 
 
Outcome variables 
Physiotherapy Usual care p value for interaction  
treatment*sub-group* 
time  
Greater dysfunction  
(n = 25) 
Lesser dysfunction 
(n = 8) 
Greater dysfunction 
(n = 24) 
Lesser dysfunction 
(n = 8) 
Primary outcome                      
     Headache frequency (days/week)  
 
1.1 (0.5 to 1.7) 
 
1.2 (0.2 to 2.2) 
 
3.1 (2.5 to 3.6) 
 
3.1 (2.1 to 4.2) 
 
0.15 
Secondary outcome 
     Headache intensity (0-10 NRS) 
 
1.2 (0.6 to 1.8) 
 
2.0 (0.9 to 3.1) 
 
3.9 (3.3 to 4.5) 
 
4.7 (3.6 to 5.7) 
 
0.20 
     Headache duration (hours/day) 1.9 (0.4 to 3.4) 2.7 (0.01 to 5.3) 4.9 (3.4 to 6.4) 6.0 (3.3 to 8.7) 0.012 
     Neck pain intensity (0-10 VAS) 1.6 (1.1 to 2.1) 1.3 (0.5 to 2.2) 4.5 (4.0 to 5.0) 5.5 (4.6 to 6.4) 0.68 
     Neck pain and disability (%) 8.1 (5.6 to 10.5) 9.6 (5.3 to 13.8) 24.9 (22.5 to27.3) 28.5 (24.1 to 32.9) 0.71 
Value are estimated mean (95% confidence interval) after adjusting for baseline values and age 
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